A nurse is assessing a client who has a prescription for cefaclor. Which of the following findings should the nurse recognize as an indication of an allergic reaction?

B) Nalbuphine: Nalbuphine is an opioid analgesic that acts on the central nervous system to relieve pain. When administered concurrently with morphine, there is a risk of additive respiratory depression and other opioid-related side effects, such as sedation and hypotension. Therefore, the nurse should clarify the prescription for nalbuphine with the provider to ensure that the combination of opioid medications is appropriate for the client's pain management. Additionally, nalbuphine has mixed agonist-antagonist properties and can precipitate withdrawal symptoms in clients who are physically dependent on full opioid agonists like morphine. Due to these potential interactions and safety concerns, it is essential for the nurse to obtain clarification from the provider before administering nalbuphine to the client receiving morphine via a PCA pump.

A) Ondansetron: Ondansetron is an antiemetic medication commonly prescribed to manage nausea and vomiting, which can be side effects of opioid analgesics like morphine. There are no significant contraindications or interactions between ondansetron and morphine, making it a suitable choice for adjunctive therapy in clients receiving PCA morphine for cancer pain.

C) Insulin glargine: Insulin glargine is a long-acting insulin analog used to control blood glucose levels in clients with diabetes mellitus. While clients with cancer may have comorbidities such as diabetes, the prescription for insulin glargine is unlikely to require clarification in the context of concurrent morphine use. However, the nurse should verify the client's current blood glucose levels and adjust the insulin dosage as needed based on the client's glycemic control.

D) Acetaminophen: Acetaminophen is a non-opioid analgesic commonly used to manage mild to moderate pain. When used in combination with opioids like morphine, acetaminophen can provide additive pain relief and may reduce the total opioid dosage required. There are no significant contraindications or interactions between acetaminophen and morphine, making it a suitable choice for adjunctive pain management in clients receiving PCA morphine for cancer pain.

A) Ex edicationr bubble from the syringe prior to administering the medication: Expelling air bubbles is necessary when administering medications via intravenous injection to prevent air embolisms. However, with subcutaneous injections like enoxaparin, the presence of small air bubbles is not usually a concern, and expelling them is not necessary.

B) Administer the medication into the anterolateral or posterolateral abdominal area: This is the correct action for administering enoxaparin. Enoxaparin is typically administered subcutaneously into the anterolateral or posterolateral abdominal wall. This site is preferred due to its high vascularity and good absorption of the medication.

C) Hold the skin taut at the injection site while administering the medication: While holding the skin taut can help reduce discomfort during the injection, it is not always necessary. The choice to hold the skin taut depends on the client's body habitus and the nurse's preferenc’. It is not a specific requi’ement for administering enoxaparin.

D) Massage the injection site after administering the medication: Massaging the injection site after administering enoxaparin is not recommended. It can increase bruising or bleeding at the injection site. Instead, after administering the medication, the nurse should apply gentle pressure with a dry cotton ball or gauze pad to help minimize bleeding.